Payment overview · 2025
General Payments
$1,885.28
111 reported records · 21 companies
Healthcare provider profile · identity verified
Richard P Townsend, MD
Allopathic & Osteopathic Physicians|Family Medicine · RICHARDSON, TX · NPI 1194752642
Verified facts
What the public records show
CMS Open Payments records show Richard P Townsend, MD received $1,885.28 in general payments during 2025 across 111 reported records.
Amgen Inc. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $246.12 | 13.1% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.02 | 12.4% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $204.78 | 10.9% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $180.65 | 9.6% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $135.10 | 7.2% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $109.22 | 5.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.14 | 5.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.97 | 4.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $90.30 | 4.8% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.09 | 4.7% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.95 | 4.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $68.62 | 3.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.99 | 3.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $56.22 | 3.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.65 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.52 | 1.3% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $23.94 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.29 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.11 | 0.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $14.03 | 0.7% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.57 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,885.28 | 111 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $180.65 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $163.72 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $152.27 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $148.11 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.18 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $136.57 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $109.22 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $98.67 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $91.97 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $90.30 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $89.09 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $76.58 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $68.76 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $68.62 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $56.22 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.51 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.21 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.21 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.76 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 22 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 48 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 207 |
| Levothyroxine Sodium | Levothyroxine Sodium | 643 | 180 |
| Losartan Potassium | Losartan Potassium | 398 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 124 |
| Lisinopril | Lisinopril | 379 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 120 |
| Metformin Hcl | Metformin Hcl | 315 | 99 |
| Trazodone Hcl | Trazodone Hcl | 274 | 78 |
| Gabapentin | Gabapentin | 269 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 240 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 70 |
| Allopurinol | Allopurinol | 219 | 62 |
| Meloxicam | Meloxicam | 219 | 64 |
| Tramadol Hcl | Tramadol Hcl | 198 | 53 |
| Omeprazole | Omeprazole | 189 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 56 |
| Glimepiride | Glimepiride | 170 | 50 |
| Simvastatin | Simvastatin | 161 | 47 |
| Furosemide | Furosemide | 159 | 55 |
| Montelukast Sodium | Montelukast Sodium | 156 | 47 |
| Alprazolam | Alprazolam | 153 | 43 |
| Carvedilol | Carvedilol | 138 | 40 |
| Fenofibrate | Fenofibrate | 136 | 38 |
| Mounjaro | Tirzepatide | 134 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 40 |
| Ozempic | Semaglutide | 127 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 31 |
| Metformin Hcl Er | Metformin Hcl | 121 | 39 |
| Celecoxib | Celecoxib | 116 | 34 |
| Ezetimibe | Ezetimibe | 114 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 35 |
| Azithromycin | Azithromycin | 94 | 82 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 28 |
| Sertraline Hcl | Sertraline Hcl | 88 | 27 |
| Finasteride | Finasteride | 85 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 21 |
| Eliquis | Apixaban | 73 | 18 |
| Synthroid | Levothyroxine Sodium | 72 | 20 |
| Lorazepam | Lorazepam | 71 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 21 |
| Clonazepam | Clonazepam | 66 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 22 |
| Glipizide | Glipizide | 51 | 13 |
| Diazepam | Diazepam | 49 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 13 |
| Valsartan | Valsartan | 48 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 23 |
| Lovastatin | Lovastatin | 46 | 15 |
| Potassium Chloride | Potassium Chloride | 45 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Jardiance | Empagliflozin | 40 | 14 |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | 11 |
| Atenolol | Atenolol | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 11 |
| Famotidine | Famotidine | 36 | 13 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 11 |
| Temazepam | Temazepam | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 28 |
| Colchicine | Colchicine | 32 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 15 |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 14 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 27 |
| Ondansetron Odt | Ondansetron | 30 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Prolia | Denosumab | 29 | 19 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 11 |
| Methylprednisolone | Methylprednisolone | 26 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 18 |
| Latanoprost | Latanoprost | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 12 |
| Probenecid | Probenecid | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,885.28 · 111 records | Amgen Inc. | AIRSUPRA, AREXVY, BREZTRI, CONTRAVE, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, JARDIANCE, JATENZO, KISUNLA, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, VRAYLAR, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error